

Accepted Manuscript

Molecular Targets for Cancer Therapy in the PI3K/AKT/mTOR Pathway

Jiri Polivka Jr., Filip Janku

PII: S0163-7258(13)00240-4
DOI: doi: [10.1016/j.pharmthera.2013.12.004](https://doi.org/10.1016/j.pharmthera.2013.12.004)
Reference: JPT 6635

To appear in: *Pharmacology and Therapeutics*



Please cite this article as: Polivka, J. Jr. & Janku, F., Molecular Targets for Cancer Therapy in the PI3K/AKT/mTOR Pathway, *Pharmacology and Therapeutics* (2013), doi: [10.1016/j.pharmthera.2013.12.004](https://doi.org/10.1016/j.pharmthera.2013.12.004)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

P&T # 22492

Molecular Targets for Cancer Therapy in the PI3K/AKT/mTOR PathwayJiri Polivka Jr.,^{1,2} Filip Janku³

¹ Department of Histology and Embryology and Biomedical Centre, Faculty of Medicine Plzen, Charles University Prague, Husova 3, 301 66 Plzen, Czech Republic

² Department of Neurology, Faculty Hospital Plzen, Alej svobody 80, 304 60 Plzen, Czech Republic

³ Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

Address for correspondence:

Filip Janku, MD, PhD

Department of Investigational Cancer Therapeutics; The University of Texas MD Anderson Cancer Center; 1515 Holcombe Blvd., FC8.2018, Box 0455; Houston, TX 77030, USA

Email: fjanku@mdanderson.org; Phone 713-794-1226; Fax 713-563-0566

Short title: Molecular targets in the PI3K/AKT/mTOR pathway**Financial support:** Supported by MH CZ - DRO (Faculty Hospital Plzen - FNPI, 00669806) and the project ED2.1.00/03.0076 from European Regional Development Fund.**Conflict of interest:** Filip Janku received research support from Novartis, Roche, Biocartis, Transgenomic, and Trovogene.

Download English Version:

<https://daneshyari.com/en/article/5844015>

Download Persian Version:

<https://daneshyari.com/article/5844015>

[Daneshyari.com](https://daneshyari.com)